Literature DB >> 3801490

Human liver methenyltetrahydrofolate synthetase: improved purification and increased affinity for folate polyglutamate substrates.

R Bertrand, R E MacKenzie, J Jolivet.   

Abstract

Methenyltetrahydrofolate synthetase (5-formyltetrahydrofolate cyclodehydrase (cyclo-ligase) (ADP-forming) EC 6.3.3.2) catalyzes the ATP- and Mg2+-dependent transformation of 5-formyltetrahydrofolate (leucovorin) to 5,10-methenyltetrahydrofolate. The enzyme has been purified 49,000-fold from human liver by a two-column procedure with Blue Sepharose followed by folinate-Sepharose chromatography. It appears as a single band both on SDS-polyacrylamide gel electrophoresis (Mr 27,000) and on isoelectric focusing (pI = 7.0) and is monomeric, with a molecular weight of 27,000 on gel filtration. Initial-velocity studies suggest that the enzyme catalyzes a sequential mechanism and at 30 degrees C and pH 6.0 the turnover number is 1000 min-1. The enzyme has a higher affinity for its pentaglutamate substrate (Km = 0.6 microM) than for the monoglutamate (Km = 2 microM). The antifolate methotrexate has no inhibitory effect at concentrations up to 350 microM, while methotrexate pentaglutamate is a competitive inhibitor with a Ki = 15 microM. Similarly, dihydrofolate monoglutamate is a weak inhibitor with a Ki = 50 microM, while the pentaglutamate is a potent competitive inhibitor with a Ki of 3.8 microM. Thus, dihydrofolate and methotrexate pentaglutamates could regulate enzyme activity and help explain why leucovorin fails to rescue cells from high concentrations of methotrexate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3801490     DOI: 10.1016/0167-4838(87)90004-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Investigations of amino acids in the ATP binding site of 5,10-methenyltetrahydrofolate synthetase.

Authors:  Meagan Tolley; Lydia Bickford; Kristen Clare; Timothy W Johann
Journal:  Protein J       Date:  2012-08       Impact factor: 2.371

2.  PharmGKB summary: methotrexate pathway.

Authors:  Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

3.  Methenyltetrahydrofolate synthetase is a high-affinity catecholamine-binding protein.

Authors:  Montserrat C Anguera; Patrick J Stover
Journal:  Arch Biochem Biophys       Date:  2006-10-04       Impact factor: 4.013

4.  Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts.

Authors:  J A Houghton; L G Williams; S K Loftin; P J Cheshire; C L Morton; P J Houghton; A Dayan; J Jolivet
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  5,10-Methenyltetrahydrofolate synthetase activity is increased in tumors and modifies the efficacy of antipurine LY309887.

Authors:  Martha S Field; Montserrat C Anguera; Rodney Page; Patrick J Stover
Journal:  Arch Biochem Biophys       Date:  2008-11-08       Impact factor: 4.013

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.